Are registries the key to advancing treatment of rare cancers?  We hope to find answers to that question and to identify obstacles blocking the promise of registries and solutions to overcome those challenges in the FDA-PDS Symposium IX on Oct. 7.

This symposium will be held online for the first time but the goal is the same as in past years: elevate the conversation about this research area, which is ripe for fresh attention and energy from academia, industry and FDA. The event will run from noon until about 3 pm EDT.

We are honored and excited to welcome keynote speaker Dr. David Fajgenbaum, a groundbreaking physician-scientist, disease hunter, speaker, and author of the national bestselling memoir, Chasing My Cure: A Doctor’s Race to Turn Hope Into Action.

Fajgenbaum nearly died five times battling Castleman disease. To try to save his own life, he developed and led an innovative approach to research through the Castleman Disease Collaborative Network (CDCN) and discovered a possible treatment that has put him into an extended remission.

We are eager to hear the unique perspectives and insights of Dr. Fajgenbaum. This is a session that’s sure to inspire.

The symposium brings together multiple stakeholders representing most aspects of the rare disease challenge: practice in the clinic, pharmaceutical research, policy and regulatory science, and patient advocacy to brainstorm the operational dynamics between the groups.

Mark your calendar.  More details and registration information will be coming via email soon.